Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04732624
Other study ID # STUDY00010934
Secondary ID D43TW009345
Status Completed
Phase Phase 3
First received
Last updated
Start date September 30, 2021
Est. completion date June 4, 2022

Study information

Verified date October 2023
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nepal and the South Asian sub-continent carry some of the highest rates of burn injury globally, with an associated high morbidity and mortality. Nepal currently has one major center equipped for burn care, in Kirtipur, Nepal and receives referred patients from around the country. At presentation, most patients with major burns have had minimal to no resuscitation on arrival, often hours to days after the burn injury was sustained. Timely fluid resuscitation, initiated as soon as possible after major burn injury, is the main tenet of acute burn care. Lack of adequate resuscitation in major burn injuries leads to kidney injury, progression of burn injury, sepsis, burn shock, and death. The current standard of care for major burn resuscitation is intravenous fluid resuscitation. In Nepal, however, adequately trained and equipped hospitals for treatment of burn care are not available (for a variety of reasons). Additionally, there is not a systematic emergency medical transport system available for provision of medical care and resuscitation during transport. Enteral-based resuscitation with substances like the WHO Oral Rehydration Solution (ORS) is recommended by burn experts and the professional burn societies when resources and access to intravenous fluid resuscitation are not available in resource-constrained settings such as rural areas, low- and middle-income countries, and military battlefield scenarios. Studies have previously demonstrated the efficacy and safety of enteral-based resuscitation in controlled, high-resource settings, however there have not been real-world effectiveness trials in austere settings. Therefore, the investigators seek to ultimately address the problem of pre-hospital and pre-burn center admission resuscitation by studying the feasibility and effectiveness of enteral resuscitation with Oral Rehydration Solution (ORS) in preventing burn shock. This study examines enteral (oral)-based resuscitation with ORS and IV Fluids versus only IV Fluids for the treatment of major burn injuries. The intervention portion of the study will entail randomization of patients presenting with acute burn injuries of 20-40% total body surface area (TBSA) to an enteral-based resuscitation versus the standard of care IV fluid resuscitation. The intervention will continue through the 24-72 hours of the acute resuscitation period. This is a feasibility study, primarily to develop and establish the research infrastructure and practices at the study site for future pilot study and eventually randomized-controlled trial research on this intervention. The primary outcomes will be measures of feasibility such as the adherence rate to the resuscitation protocols. Further, there will be a qualitative component to the study with focus group interviews of the bedside healthcare providers (doctors and nurses) who are caring for the enrolled patients, in order to understand the challenges and facilitators of enteral resuscitation. Qualitative analysis will be done to understand the major themes of challenges and facilitators to enteral resuscitation.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 4, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All genders - Adults aged =18 years who present with moderate-sized burn injuries [20 - 40% total body surface areas (TBSA)] to the Nepal Cleft and Burn Center within 24 hours of injury. Exclusion Criteria: - Patients with electrical burns, chemical burns, inhalation injury. - Patients in overt shock (defined as serum lactate >2.5, or hypotension and altered mental status). - Pregnant patients, psychiatrically unstable patients will be excluded. - Patients with oropharyngeal defects and/or previously known diagnoses leading to high risk of aspiration, and/or precluding safe nasal-enteric access will be excluded. - Patients will history of chronic nausea and/or vomiting, including those with a diagnosis of gastroparesis due to diabetes mellitus will be excluded. - Patients with a Baux score of over 100 (age + TBSA), patients with declared palliative intent on admission, and patients for whom clinicians have high level of clinical concern based on clinical judgement will also be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oral Rehydration Solution
Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
Lactated Ringer
Standard-of-care Intravenous Fluid resuscitation

Locations

Country Name City State
Nepal Nepal Cleft and Burn Center at Kirtipur Hospital Kirtipur Bagmati

Sponsors (2)

Lead Sponsor Collaborator
University of Washington Fogarty International Center of the National Institute of Health

Country where clinical trial is conducted

Nepal, 

Outcome

Type Measure Description Time frame Safety issue
Primary 24 Hour Average Urine Output (UOP) Calculated by totaling all of the recorded urine output (adding up the columns labelled HR 1-2 UO, HR 3-4 UO, etc. until HR 23-24), then dividing by their weight in Kg (column labelled Admission weight) and dividing by 24 hours. The units of this measurement will be mL/kg/hr. 24 hours
Primary 24-hour Resuscitation Volume Calculated by totaling the total resuscitative fluids administered in first 24 hours of resuscitation, divided by admission weight and % TBSA of burn injury. (cc/kg/% TBSA of burn injury) 24 hours
Primary Hours From Injury to Resuscitation Hours calculated from point of injury to starting of resuscitation. Point measurement (Once at the start of resuscitation)
Secondary Number of Participants With GI Discomfort Any "check" for nausea, vomiting, distention, diarrhea 24 hours
Secondary Number of Participants Crossover to IV Due to GI Intolerance Number of participants crossover to standard of care (IV resuscitation) due to GI intolerance like nausea, vomitting 24hours
Secondary Number of Participants With Acute Kidney Injury Measured with any signs of Acute Kidney injury during first 72 hours of resuscitation according to KDIGO definition i.e., increase in serum creatinine by 0.3mg/dL or more within 48 hours or increase in serum creatinine to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours. AKI on admission was defined as a serum creatinine greater than 1.5 mg/dL with less than 0.5 mL/kg/h of urine output for the first hour. Urine output was measured every 2 hours for the first 24 hours and serum creatinine was measured on admission then 8,16,24,48 and 72 hours from the commencement of the resuscitation. 72 hours
Secondary Participants Death Within 72 Hours of Resuscitation Secondary resuscitation outcome measured daily within study period i.e. 72 hours of resuscitation as participant death related or associated with the study. Monitored by data safety monitoring board and if proven to be associated with the study considered serious adverse event. 72 hours
Secondary Discharge Outcome Outcome of hospital stay Measured over complete course of hospitalization until discharge or death, assessed every 24 hours after enrollment in the study. Maximum timeframe 6 months.
See also
  Status Clinical Trial Phase
Completed NCT05134792 - Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients Phase 2/Phase 3
Recruiting NCT05096559 - Evaluation of Sublingual Microcirculation in Burn During Resuscitation
Recruiting NCT05559489 - Enteral Resuscitation Nepal Phase 3
Completed NCT05612867 - Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C